Astrazeneca Pharma India Share Price Target 2025, 2026, 2030, 2040, 2050

AstraZeneca Pharma India is the Indian branch of the global medicine company AstraZeneca. It makes and sells prescription medicines in India and mainly focuses on diseases like cancer, heart problems, diabetes, breathing diseases, and rare illnesses. The company is owned by AstraZeneca Plc (UK). It creates better and safer medicines, works closely with doctors and hospitals, and helps patients get the right treatment. It also supports public health in India, including work on vaccines and long-term diseases that affect many people.

What is Astrazeneca Pharma India Ltd NSE: ASTRAZEN?

AstraZeneca Pharma India is a well-known medicine company in India, established in 1979, and located in Bengaluru. It makes and sells prescription medicines for serious health problems like cancer, heart disease, breathing problems, and other long-term illnesses. The company brings modern and well-researched medicines from its global parent to patients in India and works closely with doctors and hospitals. It focuses on safe medicines, new ideas, and better treatment for patients. The company also helps more people get good-quality medicines and better healthcare across India.

Astrazeneca Pharma India Share Price Target

Astrazeneca Pharma India Share Price Target 2025

It plays an important role in the global group and mainly focuses on the healthcare needs of people in India. It develops, produces, and sells prescription medicines used to treat serious and long-term diseases. The company follows a science-based approach; its medicines are made after careful research and testing. Over the years, it has earned trust from doctors, hospitals, and patients because of its focus on safety, quality, and innovation. In 2025, its share price target would be ₹10691, as per stock market analysts.

Its share price would be between ₹6619 to ₹10691 in 2025, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	6619	10691

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	6619	7529
February	6670	7726
March	6620	9060
April	7201	9211
May	7800	8700
June	8400	10691
July	8822	9650
August	7955	9221
September	8403	9242
October	9000	9599
November	8828	9849
December	8297	10250

Astrazeneca Pharma India Share Price Target 2026

It is owned by AstraZeneca Plc from the United Kingdom. Even though the parent company is from another country, the Indian company is registered and listed in India and follows Indian rules and laws. This setup allows it to use global research knowledge while understanding the needs of Indian patients. The Indian team gains knowledge from worldwide scientific experience while keeping its focus on improving healthcare in India. In 2026, its share price target would be ₹14980, as per stock market analysts.

Its share price would be between ₹10125 to ₹14980 in 2026, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2026	10125	14980

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	10125	10874
February	10424	11257
March	10744	11557
April	10994	11874
May	11241	12240
June	11774	12775
July	12058	13112
August	12224	13354
September	12557	13587
October	12785	14354
November	13124	14678
December	14210	14980

Share Price Target 2027

The company works to understand diseases better and find improved ways to treat them. Research and new ideas are important parts of its daily work. Its medicines are made after years of research, testing, and clinical trials. This approach helps the company create treatments for diseases that are difficult to manage. Using modern science and medical knowledge helps doctors give better care and helps patients live healthier lives. In 2027, its share price target would be ₹18880, as per stock market analysts.

Its share price would be between ₹14587 to ₹18880 in 2027, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2027	14587	18880

Share Price Target 2028

It mainly works in serious disease areas. These include cancer, heart problems, kidney and metabolic disorders, breathing problems such as asthma, and rare diseases. Many of these illnesses need long-term treatment and careful medical supervision. The company focuses on these areas because they affect many people and often have limited treatment options. Its advanced medicines help doctors treat complex diseases more effectively. In 2028, its share price target would be ₹22782, as per stock market analysts.

Its share price would be between ₹18478 to ₹22782 in 2028, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2028	18478	22782

Share Price Target 2029

It follows strict rules for making medicines and checking quality. Its production facilities meet international safety and quality standards. Every step of making the medicine is carefully checked, from raw materials to final packaging. Regular testing ensures that medicines are safe and work properly for patients. A strong focus on quality reduces mistakes and builds trust among doctors and healthcare professionals. In 2029, its share price target would be ₹26900, as per stock market analysts.

Its share price would be between ₹22358 to ₹26900 in 2029, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2029	22358	26900

Astrazeneca Pharma India share price Target 2030

It works with many partners to improve healthcare in India. These include doctors, hospitals, research centres, and healthcare organisations. The company supports health awareness programs, training for doctors, and better treatment practices. Working together helps reach more patients and makes medicines easier to access. These collaborations allow the company to have a bigger positive impact on patient care and strengthen the healthcare system across India. In 2030, its share price target would be ₹31200, as per stock market analysts.

Its share price would be between ₹26690 to ₹31200 in 2030, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2030	26690	31200

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	26690	27874
February	26954	28124
March	27354	28457
April	27587	28668
May	27945	28997
June	28125	29154
July	28558	29541
August	28874	29787
September	29121	30224
October	29557	30414
November	29789	30787
December	30557	31200

Share Price Target 2040

It plays an important role in improving public health in the country. Its medicines help treat serious and long-term illnesses that affect many people. The company also supports health programs that aim to reduce the effects of chronic diseases. It focuses on early treatment, prevention, and effective medicines to improve overall health results. Its work helps doctors, hospitals, and health systems provide better care to patients across the country. In 2040, its share price target would be ₹57738, as per stock market analysts.

Its share price would be between ₹52317 to ₹57738 in 2040, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2040	52317	57738

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	52317	53124
February	52657	53557
March	53000	54115
April	53224	54589
May	53547	55235
June	53847	55874
July	54124	56124
August	54557	56742
September	54897	57000
October	55647	57254
November	56647	57557
December	56887	57738

Share Price Target 2050

The company uses modern technology to improve work and healthcare delivery. The company also uses all the latest digital tools to communicate better with doctors and healthcare providers. Technology is also used in research, data analysis, and daily business tasks. These tools help the company make better decisions and improve patient care. Using digital solutions helps the company adapt to changing healthcare needs and continue providing better support and services to doctors and patients. In 2050, its share price target would be ₹86874, as per stock market analysts.

Its share price would be between ₹80775 to ₹86874 in 2050, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2050	80775	86874

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	80775	81745
February	80954	82254
March	81114	82767
April	81547	83334
May	81788	83558
June	81998	84214
July	82547	84557
August	83451	84987
September	84410	85541
October	84847	85897
November	85214	86357
December	85547	86874

Should I buy Astrazeneca Pharma India stock?

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	6619	10691
2026	10125	14980
2027	14587	18880
2028	18478	22782
2029	22358	26900
2030	26690	31200
2040	52317	57738
2050	80775	86874

It could be a good choice for people who want to invest in healthcare for the long term. The company makes important medicines for serious and long-lasting illnesses and works with its global parent company and partners to grow. Its medicines are trusted by doctors for their quality and research. This stock is better for investors looking for steady, long-term returns, not quick profits, and it should fit your personal goals and comfort with risk.

Astrazeneca Pharma India earnings results

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales +	832	814	806	1,003	1,296	1,716	2,006
Expenses +	711	678	719	838	1,111	1,462	1,687
Operating Profit	121	135	86	165	184	254	320
OPM %	15%	17%	11%	16%	14%	15%	16%
Other Income +	13	13	15	-14	51	-56	-3
Interest	1	1	1	1	1	1	2
Depreciation	19	20	17	16	15	40	46
Profit before tax	114	127	83	134	220	156	268
Tax %	37%	27%	26%	26%	26%	26%
Net Profit +	72	93	62	99	162	116	199
EPS in Rs	28.88	37.32	24.64	39.72	64.60	46.30	79.66
Dividend Payout %	3%	5%	41%	40%	37%	69%	—

Key Metrics

TTM PE Ratio	PB Ratio	Dividend Yield	Sector PE	Sector PB	Sector Div Yld
114.93	29.71	0.35%	36.65	5.78	0.59%

Peers & Comparison

Stock	PE Ratio	PB Ratio	Dividend Yield
Astrazeneca Pharma India Ltd	197.75	29.71	0.35%
Sun Pharmaceutical Industries Ltd	39.37	5.94	0.89%
Torrent Pharmaceuticals Ltd	67.14	16.91	0.84%
Cipla Ltd	23.25	3.92	1.05%

Is Astrazeneca Pharma India stock good to buy? (bull case & bear case)

Bull Case:

• Its revenue grew about 32% to ₹1,756.9 crore in FY25 from ₹1,330.3 crore in FY24, showing strong top‑line growth.
• This company’s Q4 FY25 sales rose about 25% to ₹480.5 crore compared with the same quarter last year.
• It reported EBITDA of around ₹294.6 crore (+34% YoY) in FY25, indicating better earnings before interest and tax.
• Promoter shareholding is high and stable at ~75%, reflecting confidence from major owners.
• The company has no debt.
• The company’s profit has grown steadily at about 19.4% per year over the last five years.
• The company has been paying a good dividend, around 48.8% of its profits.

Bear Case:

• It saw net profit fall about 28% to ₹115.7 crore in FY25 compared with ₹161.5 crore in FY24, which may concern earnings growth.
• This company’s net profit margin declined to about 6.7%, showing pressure on profitability.
• Profit margins and ROE have dipped compared with earlier periods, suggesting slower profit efficiency.
• Its stock is trading at 28.6 times its book value.

Conclusion

It is a good choice for long-term investors. The company has steady sales growth, strong profits, very low debt, and pays regular dividends, showing it is financially stable. Its medicines are trusted by doctors, and it works with hospitals and partners to improve healthcare in India. The stock is a bit expensive, and profit margins have some pressure, so it is better for investors looking for steady, long-term growth, not quick profits.

FAQs